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MATERIALS AND METHODS:
We created a decision analysis model using TreeAgePro (TreeAge Software Inc.; Williamstown, MA). Figure 1 represents a simplified diagram of our decision tree. Effectiveness outcomes included ovarian cancer incidence and mortality as well as major surgical complications. Modeled complications included transfusion, conversion to laparotomy or laparoscopy, abscess/hematoma requiring intervention, ileus, readmission, and reoperation within 30 days. We also modeled subsequent benign adnexal surgery beyond the postoperative window. Those whose procedures were converted from a vaginal route were assumed to undergo salpingectomy regardless of treatment group, following ACOG guidelines. Costs were gathered from published literature and Medicare reimbursement data, with internal cost data from 892 hysterectomies used to estimate costs when necessary. Complication rates were determined from published literature and from 13,397 vaginal hysterectomies recorded in the National Surgical Quality Improvement Program database from 2008-2013. RESULTS: Switching from a policy of vaginal hysterectomy alone to a policy of routine planned salpingectomy prevents 1 in 225 ovarian cancer cases, and 1 in 450 ovarian cancer deaths. Overall, salpingectomy was a less expensive strategy than not performing salpingectomy ($7,350.62 vs. $8,113.45) . This effect persisted when costs of treating cancer were excluded from the analysis ($6,860.87 vs. $7,197.08 ). This second analysis was performed as we wanted to ensure the high costs of treating cancer were not skewing our results. Given that salpingectomy is both more effective and has lower cost, it is considered the "dominant" strategy and further cost-effectiveness analysis with incremental cost effectiveness ratios and willingness to pay thresholds is unnecessary. Sensitivity analysis demonstrated the driving force behind increased costs was the increased risk of subsequent benign adnexal surgery among women retaining their tubes. We therefore performed an additional analysis where subsequent benign adnexal surgery was removed from the model to eliminate the impact of that variable. Salpingectomy became the more expensive strategy when cancer treatment costs were also excluded. In this secondary analysis, it costs $1,196.99 to prevent 1 case of cancer. Planned opportunistic salpingectomy had more major complications than hysterectomy alone (7.95% vs. 7.68%). Therefore, routine salpingectomy results in 0.61 additional complications per case of cancer prevented and 1.21 additional complications per death prevented. CONCLUSION: Salpingectomy should routinely be performed with vaginal hysterectomy as it was the dominant and therefore costeffective strategy. Complications are minimally increased, but the trade-off with cancer prevention is highly favorable.
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OBJECTIVES:
The American Congress of Obstetricians and Gynecologists (ACOG) recommends that "the surgeon and patient should discuss the potential benefits of the removal of the fallopian tubes during a hysterectomy in women at population risk of ovarian cancer who are not having an oophorectomy," resulting in an increasing rate of salpingectomy at the time of hysterectomy. Rates of salpingectomy are highest for laparoscopic (>60%) and lowest for vaginal (<20%) hysterectomy. The objectives of this study were to determine whether bilateral salpingectomy is feasible in the majority of planned vaginal hysterectomies and to assess its impact on operating time, estimated blood loss (EBL), surgical complications, and menopausal symptoms. MATERIALS AND METHODS: This was a multicenter, prospective, observational study of patients undergoing planned vaginal hysterectomy with bilateral salpingectomy. At baseline, demographic and relevant medical data were collected. Surgical procedure, intraoperative findings, operative time, and EBL for salpingectomy were recorded. Uterine weight and pathology reports for all fallopian tubes were reviewed. Patients completed the Menopause Rating Scale (MRS) at baseline and at post-operative follow-up (6-12 weeks). Descriptive analyses and logistic regression were performed to characterize the sample and identify factors associated with 
